doi: 10.3390/cells9091970
Recently, after 72 weeks of treatment, adults with obesity or overweight and type 2 diabetes had a mean weight loss of 12.8% and 14.7% with 10 mg and 15 mg tirzepatide, respectively, vs 3.2% with placebo [47]
This lack of benefit stands in contrast with the significant or nearly-significant reduction in macrovascular risk reported with liraglutide, semaglutide and exenatide [51,52,53], which also enhance signaling through the GLP-1 receptor [54]
"The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms." In the UK, the most commonly used GLP-1 therapies are Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity, as well as Eli Lilly's Mounjaro (tirzepatide), which are all given as weekly injections
It is also important to note that benzyl alcohol is incompatible with certain sensitive biological tissues